Sebia, a global specialty IVD company, develops, manufactures and commercializes IVD tests & analyzers dedicated to the in vitro diagnosis and monitoring of multiple myeloma, autoimmune diseases, diabetes and hemoglobinopathies. Sebia focuses on electrophoresis techniques and is continuously investing in innovations dedicated to Multiple Myeloma with HYDRASHIFT to mitigate drug interferences, the new generation of FLC assays and recently Clonotypic Peptides Mass spectrometry for MRD testing in blood.